Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Purva Bali

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Cancer Research|April 3, 2004
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cellsFei Guo, Celia Sigua, Jianguo Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2Purva Bali, Michael Pranpat, Ramona Swaby, et al.
Blood|April 20, 2002
Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosisFei Guo, Ramadevi Nimmanapalli, Shanthi Paranawithana, et al.
Cancer Research|January 9, 2003
Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosisSylvie Wittmann, Purva Bali, Sreenivasa Donapaty, et al.
Blood|October 30, 2004
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3Prince George, Purva Bali, Srinivas Annavarapu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90Warren Fiskus, Yuan Ren, Alex Mohapatra, et al.
The Journal of Biological Chemistry|June 7, 2005
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitorsPurva Bali, Michael Pranpat, James Bradner, et al.
Cancer Research|May 20, 2004
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3Prince George, Purva Bali, Pamela Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cellsWarren Fiskus, Michael Pranpat, Maria Balasis, et al.
Cancer Research|August 28, 2003
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cellsRamadevi Nimmanapalli, Lianne Fuino, Purva Bali, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Cancer Research|April 3, 2004
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cellsFei Guo, Celia Sigua, Jianguo Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2Purva Bali, Michael Pranpat, Ramona Swaby, et al.
Blood|April 20, 2002
Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosisFei Guo, Ramadevi Nimmanapalli, Shanthi Paranawithana, et al.
Cancer Research|January 9, 2003
Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosisSylvie Wittmann, Purva Bali, Sreenivasa Donapaty, et al.
Blood|October 30, 2004
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3Prince George, Purva Bali, Srinivas Annavarapu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90Warren Fiskus, Yuan Ren, Alex Mohapatra, et al.
The Journal of Biological Chemistry|June 7, 2005
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitorsPurva Bali, Michael Pranpat, James Bradner, et al.
Cancer Research|May 20, 2004
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3Prince George, Purva Bali, Pamela Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cellsWarren Fiskus, Michael Pranpat, Maria Balasis, et al.
Cancer Research|August 28, 2003
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cellsRamadevi Nimmanapalli, Lianne Fuino, Purva Bali, et al.
Pageof 3